Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ovid Therapeutics Inc. - Common Stock
(NQ:
OVID
)
0.3384
+0.0079 (+2.39%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ovid Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
Next >
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
December 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
November 03, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 18, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Earnings Perspective: Return On Capital Employed
May 22, 2023
Via
Benzinga
Ovid Therapeutics: Q1 Earnings Insights
May 05, 2023
Via
Benzinga
Looking Into Ovid Therapeutics's Return On Capital Employed
March 15, 2023
Via
Benzinga
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
October 10, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
September 26, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
August 30, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
3 Very Promising Penny Stocks That Are Flying Under the Radar
August 15, 2023
Although the very concept of penny stocks to buy screams risk, these ideas just might be intriguing enough for speculators.
Via
InvestorPlace
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
August 04, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
August 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
June 28, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Added to Russell 3000® Index
June 26, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 05, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
June 14, 2023
Via
Benzinga
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
May 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
April 27, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
April 14, 2023
One executive called this the most "damaging" decision in five decades.
Via
Investor's Business Daily
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
April 12, 2023
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...
Via
Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
April 11, 2023
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...
Via
Benzinga
Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension
April 11, 2023
Via
Benzinga
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
March 09, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
March 08, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
February 28, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
February 08, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
January 05, 2023
A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.